PK STUDY OF ANTIRETROVIRAL THERAPY REGIMENS CONTAINING TENFOVIR AND ATAZANIVIR

含替福韦和阿扎尼韦的抗逆转录病毒治疗方案的药代动力学研究

• 批准号: 7716626
• 负责人: MARVIN E BELZER
• 金额: $ 1万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-20 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7716626
• 关键词: Adolescent; Adult; Age; Anti-Retroviral Agents; Atazanavir; Child; Computer Retrieval of Information on Scientific Projects Database; Dose; Drug Kinetics; Funding; Grant; HIV-1; Hour; Infection; Institution; Kinetics; Label; Measures; Persons; Pharmaceutical Preparations; Publishing; Purpose; Research; Research Personnel; Resources; Ritonavir; Source; Study Subject; Tenofovir; Treatment Protocols; United States National Institutes of Health; antiretroviral therapy; day; young adult

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is an open-label, 24-hour, single-dose pharmacokinetic study. Persons with HIV-1 infection between the ages of 18 years, 0 days and 24 years, 364 days currently on a stable combination antiretroviral regimen (>/= 28 days) with FDA-approved antiretroviral combination regimens that include tenofovir plus atazanavir/ritonavir and at least one other active antiretroviral drug will be offered participation. The purpose of this study is to measure the pharmacokinetics of atazanavir/ritonavir and tenofovir when used in combination to treat HIV-infected adolescents and young adult subjects and to compare the kinetics in these study subjects with published kinetic profiles in adults and children.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 这是一项开放标签、24 小时、单剂量药代动力学研究。 年龄在 18 岁零天至 24 岁零 364 天之间的 HIV-1 感染者，目前正在接受稳定的联合抗逆转录病毒治疗方案（>/= 28 天），其中包括 FDA 批准的抗逆转录病毒联合治疗方案，包括替诺福韦加阿扎那韦/利托那韦和将提供至少一种其他活性抗逆转录病毒药物参与。 本研究的目的是测量阿扎那韦/利托那韦和替诺福韦联合用于治疗感染艾滋病毒的青少年和青年受试者时的药代动力学，并将这些研究受试者的动力学与已发表的成人和儿童的动力学曲线进行比较。